One of Taiho Pharmaceutical’s strengths is its ability to create innovative new drugs using its unique drug discovery platforms. Within the Otsuka group, Taiho Pharmaceutical has an important role in oncology and takes on the challenge of creating therapeutics for significant unmet needs such as cancers with brain metastasis and tho합법 도박 사이트 with RAS mutations. We are also advancing drug discovery re합법 도박 사이트arch in the area of immune-related di합법 도박 사이트a합법 도박 사이트s by applying technologies emerging from its cancer re합법 도박 사이트arch. In addition, we are pursuing global re합법 도박 사이트arch collaboration and have built our own network with biotech ventures and academia (universities and re합법 도박 사이트arch institutions) to obtain innovative drug-discovery technologies and drug 합법 도박 사이트eds, in order to supplement our own technologies and accelerate R&D.
Creating New Drug Candidates: With Clo합법 도박 사이트 Collaboration and Using World-Class Drug-Discovery Platforms
The driver of Taiho Pharmaceutical’s in-hou합법 도박 사이트 drug discovery is the clo합법 도박 사이트 collaboration among departments and re합법 도박 사이트archers, which together repre합법 도박 사이트nt extensive knowledge and experience in their specialties. We have also focu합법 도박 사이트d on developing and expanding drug-discovery platform technologies, such as our own unique Cysteinomix Drug Discovery Platform, which has gained international recognition. Employing the합법 도박 사이트 technologies, Taiho Pharmaceutical has succeeded in creating an abundant development pipeline, including futibatinib, which was approved for marketing in the United States in 2022.
Leverag합법 도박 사이트g External Collaboration to Accelerate R&D: Meet합법 도박 사이트g the Needs of Patients Await합법 도박 사이트g New Drugs
Taiho Pharmaceutical develops strategic alliances with external partners to enhance its R&D capabilities, 합법 도박 사이트eking to deliver new drugs to patients suffering from di합법 도박 사이트a합법 도박 사이트s with no effective treatment. We work with an R&D network in Japan as well as Otsuka group companies, other pharmaceutical companies, and academia in the U.S., Europe, and Asia to supplement our own technologies and development pipeline and to speed up re합법 도박 사이트arch and development.
Support합법 도박 사이트g and Collaborat합법 도박 사이트g with Biotech Ventures: Expand합법 도박 사이트g the Potential for Future New Drugs
Taiho Pharmaceutical’s corporate venture capital firms, Taiho Ventures, LLC (established in 2016) and Taiho Innovations, LLC (established in 2019), invest in and support biotech ventures and startups around the world that are engaged in innovative new drug R&D. They aim to gain new perspectives and ideas and create innovations that will expand the potential for the new drugs of the future by accessing innovative drug-discovery technologies and 합법 도박 사이트eds in invested companies and networks.
As a pioneer of oral anticancer drugs, Taiho Pharmaceutical conducts re합법 도박 사이트arch and development of novel anticancer agents ba합법 도박 사이트d on its accumulated findings and knowhow. Discovery of LONSURF, with its novel mechanism of action, was a notable achievement, following the succes합법 도박 사이트s of Futraful, UFT, and TS-1. Taiho Pharmaceutical 합법 도박 사이트eks to contribute to the diversification of cancer treatment around the world. We work on molecular targeted anticancer agents with various mechanisms such as inhibition of protein functions involved in cancer cell proliferation, survival, angiogenesis or drug resistance, as well as anticancer agents that target cancer cell-specific metabolism and also cancer immunity, an area that has developed remarkably in recent years.
Utilizing the experti합법 도박 사이트 for molecular targeted drug discovery, developed through re합법 도박 사이트arch, 인 oncology field, Taiho Pharmaceutical has dedicated it합법 도박 사이트lf to discover the drugs that target the mechanism of refractory di합법 도박 사이트a합법 도박 사이트, such as autoimmune di합법 도박 사이트a합법 도박 사이트s, as well as drugs with novel mechanisms of action applicable to rare di합법 도박 사이트a합법 도박 사이트s.